Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tauns LaboratoriesTSE:197A +0.59%14 EBITDA Margin % is 28.24% as of Mar. 2026, which is 42% below its 10-year median of 48.42. GuruFocus rates TSE:197A with a GF Score™ of 14/100. The stock has 9 warning signs investors should review. Among 814 Medical Devices & Instruments companies, Tauns Laboratories ranks better than 99.02% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tauns Laboratories's EBITDA for the
three
months ended in Mar. 2026 was 円674 Mil. Tauns Laboratories's Revenue for the
three
months ended in Mar. 2026 was 円2,387 Mil. Therefore, Tauns Laboratories's EBITDA margin for the quarter that ended in Mar. 2026 was 28.24%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tauns Laboratories EBITDA Margin % Related Terms
Tauns Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Tauns Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:197A vs ISRG, BDX, RMD: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Tauns Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tauns Laboratories EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tauns Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tauns Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tauns Laboratories (TSE:197A) has a EBITDA Margin % of 28.24% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tauns Laboratories and its competitors. This is 42% below median its historical median of 48.42. Over the past decade, Tauns Laboratories' EBITDA Margin % has ranged from 33.92 to 67.32. According to the industry distribution chart, Tauns Laboratories ranks #8 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 1%.
Is Tauns Laboratories' EBITDA Margin % too high?
Tauns Laboratories' current EBITDA Margin % of 28.24% is 42% below median its 10-year median of 48.42. Over the past 10 years, this metric has ranged from a low of 33.92 to a high of 67.32. The Medical Devices & Instruments industry median EBITDA Margin % is 7.78. Tauns Laboratories' value of 28.24% is 263% above this industry median. Based on the distribution chart, Tauns Laboratories ranks #8 out of 814 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Tauns Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Tauns Laboratories' EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tauns Laboratories ranks #8 out of 814 companies for EBITDA Margin %. This places Tauns Laboratories in the top 1% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.78. Tauns Laboratories' value of 28.24% is 263% above this benchmark. Historically, Tauns Laboratories' own EBITDA Margin % has ranged from 33.92 to 67.32 over the past decade. While the company's 10-year median is 48.42 vs. the industry median of 7.78, Tauns Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.78, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tauns Laboratories's current EBITDA Margin % of 28.24% is 263% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tauns Laboratories and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tauns Laboratories's current EBITDA Margin % is 28.24%, which is 42% below median its own 10-year median of 48.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tauns Laboratories stock overvalued right now?
Tauns Laboratories (TSE:197A) has a current EBITDA Margin % of 28.24%. The current EBITDA Margin % is 28.24%, which is 42% below median its 10-year median of 48.42 and 263% above the Medical Devices & Instruments industry median of 7.78. Tauns Laboratories' overall GF Score™ is 14/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tauns Laboratories (TSE:197A), the current EBITDA Margin % is 28.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.
14GF Score
Get the complete analysis for TSE:197A
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:197A has been successfully added to your 
